Thromboangiitis obliterans (Buerger disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Thromboangiitis obliterans (Buerger disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Thromboangiitis obliterans (TAO), also called Buerger disease, is a rare nonatherosclerotic inflammatory disorder in which blood vessels of the hands and feet become blocked. It has a strong association with smoking. Symptoms of Buerger’s disease are hand or foot pain (burning or tingling feeling), sores on toes or fingers, change in skin color or texture, and cold hands or feet. Diagnostic criteria of TAO include smoking history, onset before the age of 50 years, infra-popliteal arterial occlusions, either upper limb involvement or phlebitis migrans, and absence of atherosclerotic risk factors other than smoking. Treatment includes vasodilators like calcium channel blockers to improve blood flow, analgesics to help with pain and ulcer healing, anticoagulants to prevent blood clots, and antibiotics for ulcers. To prevent Buerger disease, patients are advised to stop tobacco use.
The Thromboangiitis obliterans (Buerger disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Thromboangiitis obliterans (Buerger disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboangiitis obliterans (Buerger disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Thromboangiitis obliterans (Buerger disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 6 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Thromboangiitis obliterans (Buerger disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Thromboangiitis obliterans (Buerger disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thromboangiitis obliterans (Buerger disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Ambulero IncAnGes Inc
Antidote Therapeutics Inc
Bilix Co Ltd
Biostar Stem Cell Research Institute
Vasogenesis Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Thromboangiitis obliterans (Buerger disease) reports